Lincoln PharmaceuticalsNSE:LINCOLN -0.65%81 Gross Margin % is 52.44% as of Mar. 2026, which is 2% above its 10-year median of 51.55. GuruFocus rates NSE:LINCOLN with a GF Score™ of 81/100 and a GF Value™ of ₹704.02 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 935 Drug Manufacturers companies, Lincoln Pharmaceuticals ranks better than 58.82% on this metric.
NSE:LINCOLN's Gross Margin % is ranked better than 58.82% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs NSE:LINCOLN: 53.63
Lincoln Pharmaceuticals had a gross margin of 52.44% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Lincoln Pharmaceuticals was 0.40% per year.
Lincoln Pharmaceuticals (NSE:LINCOLN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lincoln Pharmaceuticals had a gross margin of 52.44% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Lincoln Pharmaceuticals Gross Margin % Related Terms
Lincoln Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LINCOLN vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Gross Margin % of 52.44% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Lincoln Pharmaceuticals and its competitors. This is near median its historical median of 51.55. Over the past decade, Lincoln Pharmaceuticals' Gross Margin % has ranged from 37.43 to 53.63. According to the industry distribution chart, Lincoln Pharmaceuticals ranks #385 out of 935 companies in the Drug Manufacturers industry, placing it in the top 41.2%.
Is Lincoln Pharmaceuticals' Gross Margin % too high?
Lincoln Pharmaceuticals' current Gross Margin % of 52.44% is near median its 10-year median of 51.55. Over the past 10 years, this metric has ranged from a low of 37.43 to a high of 53.63. The Drug Manufacturers industry median Gross Margin % is 48.46. Lincoln Pharmaceuticals' value of 52.44% is 8.2% above this industry median. Based on the distribution chart, Lincoln Pharmaceuticals ranks #385 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lincoln Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lincoln Pharmaceuticals ranks #385 out of 935 companies for Gross Margin %. This puts Lincoln Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 48.46. Lincoln Pharmaceuticals' value of 52.44% is 8.2% above this benchmark. Historically, Lincoln Pharmaceuticals' own Gross Margin % has ranged from 37.43 to 53.63 over the past decade. While the company's 10-year median is 51.55 vs. the industry median of 48.46, Lincoln Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lincoln Pharmaceuticals's current Gross Margin % of 52.44% is 8.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Lincoln Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lincoln Pharmaceuticals's current Gross Margin % is 52.44%, which is near median its own 10-year median of 51.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹704.02, compared to a current price of ₹620.20 — trading 11.9% below its estimated fair value. The current Gross Margin % is 52.44%, which is near median its 10-year median of 51.55 and 8.2% above the Drug Manufacturers industry median of 48.46. Lincoln Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Gross Margin % is 52.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹620.20 is trading 11.9% below its estimated GF Value™ of ₹704.02.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
Gross Margin %: 52.44% (near median its 10-year median of 51.55)
GF Value™: ₹704.02 vs. price of ₹620.20 (11.9% below fair value)
Industry Position: 8.2% above the Drug Manufacturers median (#385 of 935)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
81GF Score
Get the complete analysis for NSE:LINCOLN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
